Myotonic Dystrophy Drug Market Expected To Touch The Value Around US$ 743.1 Mn By 2031
Myotonic dystrophy is one of the most common types of muscular dystrophy in adults, and is characterized by myotonia, myopathy, and multiorgan involvement. It is a gradually progressive, multi-system disorder that affects skeletal muscles, uterine smooth muscle, gastrointestinal smooth muscle, the heart, and the central nervous system. Certain types of myotonic dystrophy also affect endocrine glands, the spine, eyes, brain, and other organs.
The Global Myotonic Dystrophy Drug Market is projected to be US$ 409.9 Mn in 2021 to reach US$ 743.1 Mn by 2031 at a CAGR of 7.8%. The first five-year cumulative revenue (2021–2025) is projected to be over US$ 54.17 Mn, which is estimated to increase moderately over the latter part of the five-year forecast period.
Global Myotonic Dystrophy Drug Market: Market Dynamics
The increasing prevalence of muscle weakness, temporomandibular joint dysfunction, diabetes, respiratory failure, etc., are factors anticipated to further bolster the projected financial growth of this target market in the years to come. Also, both myotonic dystrophy type 1 and type 2 diseases are inherited through families in an autosomal dominant pattern. Owing to the high risk of transmission, this disease can easily be passed down from one generation to the next. This is also another factor that is slated to propel the revenue growth of the myotonic dystrophy drug industry over the forecast period.
However, strict norms concerning the approval of medications for muscular dystrophy is a major factor that is likely to restrain potential projected revenue growth opportunities for the global myotonic dystrophy drug market.
Increasing research & development activities, along with an increase in the number of clinical trials for muscular dystrophy drugs have created lucrative opportunities for the global myotonic dystrophy drug industry over this forecast period.
Global Myotonic Dystrophy Drug Market: Market Forecast
The comprehensive research report comprises a complete forecast of the global Myotonic Dystrophy Drug Market based on factors affecting the market and their impact in the foreseeable future. According to the forecast projections, revenue from the global Myotonic Dystrophy Drug Market is estimated to expand at a moderate CAGR of 7.8% during the forecast period.
Global Myotonic Dystrophy Drug Market: Segmental Snapshot
The market report has been segmented on the basis of drug type, route of administration, distribution channel, and region. The drug type segment includes Anti-Myotonic Drugs, Nonsteroidal Anti-Inflammatories (NSAIDs), Antidepressants, and Other Drug Types. The route of administration segment includes oral & intravenous. The distribution channel segment includes hospital pharmacies, retail pharmacies/drug stores and online pharmacies. The region covered in the analysis are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
By drug type: The anti-myotonic drug segment is expected to register a CAGR of over 8.9%, thereby accounting for highest revenue share among the drug type segments.
By route of administration: The oral segment is expected to register a CAGR of over 8.1%, thereby accounting for highest revenue share among the route of administration segments.
By distribution channel: The hospital pharmacies segment is expected to register a CAGR of over 9.3% over the forecast period, thereby accounting for highest revenue share among the distribution channel segments.
By region: The market in North America accounted for highest revenue share in the global Myotonic Dystrophy Drug Market in 2021, and is estimated to register a CAGR of over 8.4% between 2022 and 2031.
Global Myotonic Dystrophy Drug Market: Competitive Analysis
The research report on the global Myotonic Dystrophy Drug Market includes profiles of major companies such as Sanofi, Britol Myers Squibb Co., Pfizer Inc., C.H. Boehringer Sohn AG & Ko. KG, Teva Pharmaceutical Industries Ltd, Lupin Limited, Apotex Pharmaceutical Holdings Inc, Lannett Co, Inc, ANI Pharmaceuticals Inc.
The Global Myotonic Dystrophy Drug Market: Global Industry, Size, Share, Growth, Trends, and Forecast, 2021–2025 report has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the global Myotonic Dystrophy Drug Market for 2021–2031.
Browse More Detailed Insights Of Myotonic Dystrophy Drug Market Research Here: https://marketresearch.biz/report/myotonic-dystrophy-drug-market/